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Clopidogrel does not benefit 
early failure of arteriovenous 
fistulas in hemodialysis patients
Arteriovenous fistulas are the preferred type of vascular access 
for hemodialysis because they have lower thrombosis, infec-
tion rates, and health-care expenditures than synthetic grafts 
or central venous catheters. Early failure of fistulas due to 
thrombosis or inadequate maturation is a barrier to increas-
ing the prevalence of fistulas among patients on hemodialy-
sis. Small, inconclusive trials have suggested that antiplatelet 
medications may reduce thrombosis of new fistulas.
In a new study, Dember et al. evaluated the effect of clopi-
dogrel, a medication commonly used to prevent blood clots, 
on the outcome of fistula thrombosis 6 weeks after its for-
mation. Subjects were randomized to receive clopidogrel (a 
300 mg loading dose followed by a daily dose of 75 mg) or 
placebo. The study drug was started within 1 day after the fis-
tula formed and continued for 6 weeks. The trial was stopped 
early, after 877 subjects were randomized. At that time, fistula 
thrombosis had occurred in 12.2% of subjects receiving clopi-
dogrel and 19.5% receiving placebo (P = 0.018). However, 
failure of the fistula to attain suitability for dialysis was no 
different between treatment arms (61.8% versus 59.5% in 
clopidogrel and placebo arms, respectively; P = 0.40). Adverse 
events, including bleeding, were not different between 
treatment groups. Although clopidogrel lowered the risk of 
thrombosis 6 weeks later, it did not increase the rate of suit-
ability for dialysis. One resulting hypothesis is that atten-
tion should be given to appropriate hemodynamic stresses 
rather than coagulation. In addition to providing a new track 
of investigation, the data showing an expectation of fistula 
maturation in roughly 60% of subjects can help influence 
clinical practice guidelines and expectations among differ-
ent populations to weigh the balance between maximizing 
the working fistulas and maintaining the numbers of fistulas 
that fail to mature.
This study is the first to be published by the Dialysis Access 
Consortium, a National Institutes of Health-funded network 
of academic centers whose objective is to design and execute 
studies aimed at prolonging dialysis access survival. (JAMA 
2008; 299: 2164–2171)
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Diabetic eNOS knockout mice 
develop complications  
of diabetes
Accelerated atherosclerosis and nephropathy are among the 
most common complications of diabetes. Nitric oxide (NO) 
acts as a potent modulator of renal function and controls both 
afferent and efferent vascular tone, glomerular ultrafiltration 
coefficient, and medullary blood flow. Thus, reduced bio-
availabilty of NO, due to impaired nitric oxide synthase (NOS) 
activity, is implicated in the cause of the above-mentioned 
conditions. Functional consequences of impaired endothelial 
NOS (eNOS) activity that cause organ-specific abnormalities 
in a diabetic setting are not completely understood. Mohan et 
al. published the results of research in which they genetically 
disrupted eNOS expression (eNOS–/–) in a diabetic mouse 
model (leprdb/db). The eNOS–/–/leprdb/db double-knockout 
(DKO) mice developed obesity, hyper glycemia, hyper-
insulinemia, and hypertension. Analysis of tissues from DKO 
mice showed large islets in the pancreas and fat droplets in 
hepatocytes. Interestingly, the aortae were normal, and athero-
genic lesions were not observed. Abnormalities in the aorta 
included poor re-endothelialization and increased medial 
wall thickness (Figure), which were evident only in response 
to deliberate injury. In contrast, the authors identified sig-
nificant glomerular capillary damage in the kidney; the DKO 
mice had diabetic nephropathy similar to human disease. 
The vascular and renal impairments in DKO mice were pro-
nounced despite lower fasting plasma glucose levels than in 
leprdb/db mice, indicating that eNOS is a critical determinant 
of hyperglycemia-induced organ-specific complications and 
their severity in diabetes. These results provide evidence that 
absence of eNOS in diabetes is more harmful for the renal 
microvasculature than for the larger aortic vessel. The DKO 
model may suggest novel therapeutic strategies to prevent 
both vascular and renal complications of diabetes. (Lab Invest 
2008; 88: 515–528; doi:10.1038/labinvest.2008.23)
Marc De Broe
The remodeled abdominal aorta of DKO mice after arterial injury, 
showing increased wall thickness. Masson’s trichrome-stained 
abdominal aortic sections from control (a), leprdb/db (b), eNOS–/– (c), and 
DKO (d) mice. Original magnification, ×200. Arrows in d show remodeled 
area with increased wall thickness at the region of injury.
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Activated macrophages 
exacerbate renal injury
Macrophages are important mediators of injury in most types 
of human kidney diseases; however, the pathogenic importance 
of both macrophage quantity and activation status is unknown. 
To examine this question, Wang et al. examined the effects of an 
experimental model of human focal segmental glomeruloscle-
rosis on kidney injury. They treated severe combined immuno-
deficient mice with adriamycin nephrosis intravenously with 
either resting (1 × 106 to 5 × 106) or activated (1 × 103 to 1 × 
106) macrophages 6 days after adriamycin administration. On 
day 28, renal injury worsened in the group that received acti-
vated macrophages at doses as low as 1 × 104 macrophages per 
mouse compared with control adriamycin nephrotic mice. How-
ever, treatment with resting macrophages at doses as high as 5 × 
106 macrophages per mouse had no significant effect on either 
renal histology or function (Figure). The transferred activated 
macrophages homed to inflamed kidneys during the middle to 
late stages of the disease, but such homing was not observed in 
resting macrophages. This study of in vivo cell adoptive transfer 
demonstrates that macrophage activation status is more impor-
tant than macrophage quantity in causing renal injury. These data 
suggest that therapeutic strategies for treating progressive kidney 
diseases should target activated macrophages. (Am J Pathol 2008; 
172: 1491–1499; doi:10.2353/ajpath.2008.070825)
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Recombinant IgG Fc duplicates 
the anti-inflammatory activity  
of IVIG
High doses of monomeric immunoglobulin G (IgG) puri-
fied from intravenous immunoglobulin (IVIG) are known 
to improve the body’s anti-inflammatory activity in a vari-
ety of autoimmune settings. However, it is not clear exactly 
how those effects are mediated, because of the hetero-
geneity of IVIG. Recent studies have demonstrated that the 
anti-inflammatory activity of IgG is completely dependent on 
sialylation of the N-linked glycan of the IgG Fc fragment. The 
authors of a new study found the precise glycan requirements 
for this anti-inflammatory activity to occur, allowing them to 
engineer an appropriate IgG1 Fc fragment, an`d thus generate 
a fully recombinant, sialylated IgG1 Fc with improved potency. 
This therapeutic molecule, which defines the biologically 
active component of IVIG, may lead to the development of a 
new therapy with improved activity and availability as com-
pared with IVIG. (Science 2008; 320: 373–376; doi:10.1126/
science.1154315)
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Effect of macrophage transfusion on histological injury, macrophage 
accumulation, and fibrosis of adriamycin nephrosis. α-SMA, α-smooth 
muscle actin.
